Hydroxyurea : To Treat Sickle Cell Disease
The Indian Council of Medical Research (ICMR) is seeking to develop a pediatric oral formulation of hydroxyurea to treat sickle cell disease in India, where over 20 million individuals are affected.
- Currently, hydroxyurea is mainly available in 500 mg capsules or 200 mg tablets, making dosing for children challenging.
- This initiative is crucial, especially with the launch of the National Mission to eliminate Sickle Cell Anemia/SCD by 2047.
SCD (Sickle Cell Disease):
- Sickle Cell Disease (SCD) is a genetic disorder that affects the shape of red blood cells, causing them to become sickle-shaped instead of round.
- This abnormal shape can lead to various complications, including pain, anemia, and organ damage.
- SCD is one of the most common inherited blood disorders and can result in serious health issues, including stroke and organ failure.